Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Publication Type:
Journal Article
Authors:
Mira, J.A.;
Rivero-Juárez, A.;
Lopez-Cortes, L.F.;
Giron-Gonzalez, J.A.;
Tellez, F.;
Santos-Gil, I.D.;
Macias, J.;
Merino, D.;
Marquez, M.;
Rios-Villegas, M.J.;
Gea, I.;
Merchante, N.;
Rivero, A.;
Torres-Cornejo, A.;
Pineda, J.A.Source:
Clin Infect Dis, Volume 56, Issue 11, p.1646-1653 (2013)
Keywords:
Cohort Studies,
complications,
Death,
HCV,
hepatitis,
Hepatitis C,
hepatitis C virus,
Human,
Incidence,
interferon,
Liver,
methods,
Mortality,
Patients,
pegylated,
pegylated interferon,
Ribavirin,
sustained virologic response,
SVR,
therapy,
Time
